| Primary | Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain | A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:10, that usually is accepted as indicating protection. | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Count of Participants | | Participants | | At Day 21 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG003 | GSK2340272A INI 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the Initial process-manufactured (INI 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
| | Units | Counts |
|---|
| Participants | - OG00074
- OG00164
- OG00269
- OG003
|
| | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00074
- OG00164
- OG00269
- OG003
|
|
| |
| Primary | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease | Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/CAL/7/09. The reference seropositivity cut-off value was ≥ 1:10. | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Geometric Mean | 95% Confidence Interval | Titers | | At Day 21 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | |
|
| Secondary | Number of Subjects Who Were Seroprotected for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain | A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Count of Participants | | Participants | | At Days 0 and 42 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | |
|
| Secondary | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease | Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/CAL/7/09. The reference seropositivity cut-off value was ≥ 1:10. | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Geometric Mean | 95% Confidence Interval | Titer | | At Days 0 and 42 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | |
|
| Secondary | Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain | A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:10, that usually is accepted as indicating protection. | The ATP cohort for antibody persistence at Day 182 and 364 included all evaluable subjects for whom one or two doses were taken and for whom data concerning immunogenicity outcome measures were available. This cohort included subjects for whom assay results were available for antibodies against the study vaccine antigen component at Day 182 and 364 | Posted | | Count of Participants | | Participants | | At Days 182 and 364 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 |
|
| Secondary | Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/California/7/2009 Strain of Influenza Disease | Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/CAL/7/09. The reference seropositivity cut-off value was ≥ 1:10. | The ATP cohort for antibody persistence at Day 182 and 364 included all evaluable subjects for whom one or two doses were taken and for whom data concerning immunogenicity outcome measures were available. This cohort included subjects for whom assay results were available for antibodies against the study vaccine antigen component at Day 182 and 364 | Posted | | Geometric Mean | 95% Confidence Interval | Titers | | At Days 182 and 364 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 |
|
| Secondary | Number of Seroconverted (SCR) Subjects for HI Antibodies | Seroconversion was defined as: For initially seronegative subjects [antibody titer below (<) 1:10 post vaccination], antibody titer greater than or equal to (≥) 1:40 after vaccination; For initially seropositive subjects (antibody titer ≥ 1:10 prior to vaccination), antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was A/California/7/2009 (H1N1)v-like influenza (Flu A/CAL/7/09). | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Count of Participants | | Participants | | At Days 21 and 42 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
|
| Secondary | Number of SCR Subjects for HI Antibodies | Seroconversion was defined as: For initially seronegative subjects [antibody titer below (<) 1:10 post to vaccination], antibody titer greater than or equal to (≥) 1:40 after vaccination; For initially seropositive subjects (antibody titer ≥ 1:10 prior to vaccination), antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was A/California/7/2009 (H1N1)v-like influenza (Flu A/CAL/7/09). | The ATP cohort for antibody persistence at Day 182 and 364 included all evaluable subjects for whom one or two doses were taken and for whom data concerning immunogenicity outcome measures were available. This cohort included subjects for whom assay results were available for antibodies against the study vaccine antigen component at Day 182 and 364 | Posted | | Count of Participants | | Participants | | At Days 182 and 364 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
|
| Secondary | Number of Subjects Who Were Seroprotected for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain | A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Count of Participants | | Participants | | At Days 0, 21 and 42 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group |
|
| Secondary | Number of Subjects Who Were Seroprotected for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain | A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. | The ATP cohort for antibody persistence at Day 182 and 364 included all evaluable subjects for whom one or two doses were taken and for whom data concerning immunogenicity outcome measures were available. This cohort included subjects for whom assay results were available for antibodies against the study vaccine antigen component at Day 182 and 364 | Posted | | Count of Participants | | Participants | | At Days 182 and 364 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 |
|
| Secondary | Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease | GMFR was defined as the fold increase in serum HI geometric mean titers (GMTs) post-vaccination compared to pre-vaccination. The flu strain assessed was Flu A/CAL/7/09. | The According-to Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom one or two doses were taken and assay results were available for antibodies against H1N1 antigen for the blood sample taken 21 days after each vaccine dose. | Posted | | Geometric Mean | 95% Confidence Interval | Fold increase | | At Days 21 and 42 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group |
|
| Secondary | Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease | GMFR was defined as the fold increase in serum HI geometric mean titers (GMTs) post-vaccination compared to pre-vaccination. The flu strain assessed was Flu A/CAL/7/09. | The ATP cohort for antibody persistence at Day 182 and 364 included all evaluable subjects for whom one or two doses were taken and for whom data concerning immunogenicity outcome measures were available. This cohort included subjects for whom assay results were available for antibodies against the study vaccine antigen component at Day 182 and 364 | Posted | | Geometric Mean | 95% Confidence Interval | Fold increase | | At Days 182 and 364 | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 |
|
| Secondary | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest; prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented, who filled in their symptom sheets. | Posted | | Count of Participants | | Participants | | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 |
|
| Secondary | Number of Days With Solicited Local Symptoms | The number of days with any solicited local symptoms reported during the solicited post-vaccination period. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented, who filled in their symptom sheets. | Posted | | Median | Inter-Quartile Range | Days | | During the 7-day (Days 0-6) post-vaccination period following each dose and overall | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. |
|
| Secondary | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = temperature > 39.0 °C and ≤ 40°C. Related = symptom assessed by the investigator as related to the vaccination. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented, who filled in their symptom sheets. | Posted | | Count of Participants | | Participants | | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
|
| Secondary | Number of Days With Solicited General Symptoms | The number of days with any solicited general symptoms reported during the solicited post-vaccination period. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented, who filled in their symptom sheets. | Posted | | Median | Inter-Quartile Range | Days | | During the 7-day (Days 0-6) post-vaccination period following each dose and overall | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. |
|
| Secondary | Number of Subjects With Potential Immune-mediated Diseases (pIMDs) | Any pIMD was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration. Related pIMD was defined as an event assessed by the investigator as possibly related to the study vaccination. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented. | Posted | | Count of Participants | | Participants | | During the entire study period (from Day 0 up to Day 364) | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | |
|
| Secondary | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented. | Posted | | Count of Participants | | Participants | | Within 21 days after the first vaccination and 63 days after the second vaccination (Day 0 - Day 20 and Day 21 - Day 84) | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
|
| Secondary | Number of Subjects With Serious Adverse Events (SAEs) | SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. | The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one vaccine administration documented. | Posted | | Count of Participants | | Participants | | During the entire study period (from Day 0 up to Day 364) | | | | ID | Title | Description |
|---|
| OG000 | GSK2340272A New 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. | | OG001 | GSK2340272A New 2D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. | | OG002 | GSK2340272A INI 1D Group | Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0. |
|